Related Experiment Videos
Can hormone "resistant" breast cancer cells be inappropriately stimulated by tamoxifen?
1University of Colorado Health Sciences Center, Denver 80262.
Abstract:
We propose that the molecular heterogeneity of ER in breast tumor cells characterized by the presence of mutant receptor forms generates the cellular heterogeneity evident when PR or DNA ploidy are analyzed in cell subpopulations. Furthermore, it is likely that cellular heterogeneity leads to the lack of uniformity in response to tamoxifen that we have described. We find that heterogeneity of PR and DNA ploidy reflects existence of mixed subpopulations of breast cancer cells that are substantially remodeled under the influence of tamoxifen. It appears likely that rather than being "resistant," different subset of cells can be inhibited or stimulated by tamoxifen, and their suppression or outgrowth alters the phenotype of the tumor. PR heterogeneity of solid tumors of patients may predict for such a mixed, and potentially dangerous, response to antiestrogen treatment. As we learn more about the heterogeneity of PR, ER, and other proteins in tumors, we may be able to recognize such lethal subpopulations, which the FCM immunoassay can simply and rapidly measure. Our data also suggest that the use of tamoxifen as a chemopreventant in women at high risk of developing breast cancer should be viewed with caution.
Insights
Tumor cell heterogeneity, driven by estrogen receptor (ER) mutations, causes varied responses to tamoxifen. This suggests caution in using tamoxifen for breast cancer prevention due to potential mixed cellular effects.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Breast tumors exhibit molecular heterogeneity, particularly in estrogen receptor (ER) forms.
- This heterogeneity is linked to cellular diversity observed in progesterone receptor (PR) and DNA ploidy analyses.
- Such cellular diversity may explain inconsistent responses to tamoxifen therapy.
Purpose of the Study:
- To investigate the link between ER molecular heterogeneity and cellular heterogeneity in breast tumors.
- To understand how cellular heterogeneity influences tamoxifen response.
- To evaluate the predictive value of PR heterogeneity for tamoxifen treatment outcomes.
Main Methods:
- Analysis of molecular heterogeneity of ER in breast tumor cells.
- Assessment of cellular heterogeneity using PR and DNA ploidy analysis in cell subpopulations.
- Utilizing FCM immunoassay for rapid measurement of tumor cell subpopulations.
Main Results:
- Molecular heterogeneity of ER contributes to cellular heterogeneity in breast cancer.
- Tamoxifen treatment remodels mixed subpopulations of breast cancer cells, leading to varied responses (inhibition or stimulation).
- PR heterogeneity in tumors may predict a mixed response to antiestrogen therapy.
Conclusions:
- Cellular heterogeneity, influenced by ER and PR variations, dictates tamoxifen response in breast cancer.
- Identifying specific tumor cell subpopulations through assays like FCM immunoassay is crucial for predicting treatment outcomes.
- The use of tamoxifen as a chemopreventive agent in high-risk women warrants careful consideration due to potential adverse effects from mixed cellular responses.